早期非小细胞肺癌肠道微生物组与血清代谢组联合分析数据表1

数据集获取（Figshare）

• 源站标题：DataSheet_1_Combined analysis of gut microbiome and serum metabolomics reveals novel biomarkers in patients with early-stage non-small cell lung cancer.zip
• DOI：10.3389/fcimb.2023.1091825.s001
• 发布日期：2023-01-20
• 文件数：1 个
• 文件总体积：3.96 MB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Combined_analysis_of_gut_microbiome_and_serum_metabolomics_reveals_novel_biomarkers_in_patients_with_early-stage_non-small_cell_lung_cancer_zip/21928929

命令行下载

curl -L -o "DataSheet_1_Combined analysis of gut microbiome and serum metabolomics reveals novel biomarkers in patients with early-stage non-small cell lung cance.zip" "https://ndownloader.figshare.com/files/38900094"

文件清单

• DataSheet_1_Combined analysis of gut microbiome and serum metabolomics reveals novel biomarkers in patients with early-stage non-small cell lung cance.zip（3.96 MB）

文件总体积 3.96 MB（源站 API 实测）。

数据说明

Non-small cell lung cancer (NSCLC) is the predominant form of lung cancer and is one of the most fatal cancers worldwide. Recently, the International Association for the Study of Lung Cancer (IASLC) proposed a novel grading system based on the predominant and high-grade histological patterns for invasive pulmonary adenocarcinoma (IPA). To improve outcomes for NSCLC patients, we combined serum metabolomics and fecal microbiology to screen biomarkers in patients with early-stage NSCLC and identified characteristic microbial profiles in patients with different grades of IPA. 26 genera and 123 metabolites were significantly altered in the early-stage NSCLC patients. Agathobacter, Blautia, Clostridium, and Muribaculacea were more abundant in the early-stage NSCLC patients compared with healthy controls. For the different grades of IPA, the characteristic microorganisms are as follows: Blautia and Marinobacter in IPA grade type 1; Dorea in IPA grade type 2; and Agathobacter in IPA grade type 3. In the metabolome results, the early-stage NSCLC group mainly included higher levels of sphingolipids (D-erythro-sphingosine 1-phosphate, palmitoyl sphingomyelin), fatty acyl (Avocadyne 1-acetate, 12(S)-HETE, 20-Carboxy-Leukotriene B4, Thromboxane B3, 6-Keto-prostaglandin f1alpha, Sebacic acid, Tetradecanedioic acid) and glycerophospholipids (LPC 20:2, LPC 18:0, LPC 18:4, LPE 20:2, LPC 20:1, LPC 16:1, LPC 20:0, LPA 18:2, LPC 17:1, LPC 17:2, LPC 19:0). Dysregulation of pathways, such as sphingolipid metabolism and sphingolipid signaling pathway may become an emerging therapeutic strategy for early-NSCLC. Correlation analysis showed that gut microbiota and serum metabolic profiles were closely related, while Muribaculacea and Clostridium were the core genera. These findings provide new biomarkers for the diagnosis of early-stage NSCLC and the precise grading assessment of prognostic-related IPAs, which are of clinical importance and warrant further investigation of the underlying molecular mechanisms.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fcimb.2023.1091825.s001（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Combined_analysis_of_gut_microbiome_and_serum_metabolomics_reveals_novel_biomarkers_in_patients_with_early-stage_non-small_cell_lung_cancer_zip/21928929）。